MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
MAIA Biotechnology, Inc.AMEX: MAIA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $31.05M rose 468.6% year over year, ahead of the +129.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 546.6% from the prior quarter. Over 3 fiscal years it compounded at +12.8% a year.
Context
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +468.6% holds above the trailing-twelve-month pace of +129.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 17.91M USD
- Year-over-year change
- -1.5%
- 4-year CAGR
- +6.3%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 17.91M | -1.5% |
| FY2024 | 2024-12-31 | 18.18M | +96.1% |
| FY2023 | 2023-12-31 | 9.27M | -25.7% |
| FY2022 | 2022-12-31 | 12.48M | -11.1% |
| FY2021 | 2021-12-31 | 14.03M | — |
Financing Cash Flow vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 financing cash flow of $43.5M is the largest of the 7 companies compared; the peer median is $13.8M.
- Its year-over-year change of +129.9% is the 4th highest of 6, against a peer median of +178.3%.
- Over three fiscal years its annual growth of +12.8% compares with a peer median of +536.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $43.5M | +129.9% | +12.8% | — | |
| LTM Mar 2026 | $23.37M | +653.9% | — | — | |
| LTM Dec 2025 | $18.65M | +178.3% | -46.2% | 70.2% | |
| LTM Mar 2026 | $18.52M | -56.0% | +19474.8% | — | |
| LTM Mar 2026 | $9.08M | -55.7% | +536.8% | 609.9% | |
| LTM Mar 2026 | $1.5M | +12391.6% | — | — | |
| LTM Dec 2025 | $0 | — | — | — | |
| Peer median (excluding MAIA) | $13.8M | +178.3% | +536.8% | 340.1% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.72M | 2.32M | 3.09M | 1.91M | 2.63M |
| Change in Working Capital | 1.13M | 352.78K | 3.09M | (1.24M) | 1.5M |
| Accounts Receivables | 0 | (269.4K) | 158.41K | 56.81K | 80.41K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 805.52K | 211.35K | 471.9K | (118.83K) | 519.72K |
| Other Working Capital | 320.23K | 410.83K | 2.46M | (1.18M) | 899.19K |
| Other Non-Cash Items | 4.61M | 1M | 526.53K | 6.88M | (579.4K) |
| Operating Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 7.43M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.74M | 13.97M | 11.42M | 18.75M | 18.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 860.43K | (1.5M) | (2.15M) | (578.1K) | (617.13K) |
| Financing Cash Flow | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M |
| Effect of Forex Changes | 0 | (4.43K) | (117) | (21.55K) | (5.22K) |
| Net Change in Cash | 9.91M | 376.64K | (3.8M) | 2.45M | (943.27K) |
| Free Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.